Americans with a prescription for Lantus-branded insulin, regardless of insurance status, can now get the life-saving drug for only $35. Healthcare company GoodRx announced Thursday a partnership ...

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

Pharmaceutical giant Sanofi has capped the price of its insulin, becoming the last of ... per month price cap on Lantus for those with private insurance. Sanofi's changes follow in the footsteps ...

Sanofi India on Tuesday said it has launched ... Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs).

A 10 ml vial of Sanofi's long-acting insulin Lantus first hit the US market at $34.81 a vial in 2001, according to data from Truven Health Analytics. Since 2014, the last time Sanofi raised the ...